Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort

Zhou, Guofeng; Liu, Xiaoyu; Wang, Xiaoyi; Jin, Dayong; Chen, Yi; Li, Guoping; Li, Changyu; Fu, Deliang; Wang, Xu; Wang, Xiaolin

doi:10.2147/ott.s116136

Cited by 21 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were followed up every 3 to 5 months by a full-time clinical investigator as previously described. (Liu et al, 2016; Zhou et al, 2017)…”

Section: Methodsmentioning

confidence: 99%

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer

Liu

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

30Analysis of cell-free DNA (cfDNA) is promising for broad applications in clinical 31 settings, but with significant bias towards late-stage cancers. Although recent studies have 32 discussed the diverse and degraded nature of cfDNA molecules, little is known about its 33 impact on the practice of cfDNA analysis. Here we reported a new targeted sequencing by 34 combining single-strand library preparation and target capture (SLHC-seq). By applying 35 the new technology in plasma cfDNA from pancreatic cancer patients, we achieved higher 36 efficiency in analysis of mutations than previously reported using other detection assays. 37 SLHC-seq rescued short or damaged cfDNA fragments along to increase the sensitivity 38 and accuracy of circulating-tumor DNA detection. Most importantly, we found that the 39 small mutant fragments are prevalent in early-stage patients, which provides strong 40 evidence for fragment size-based early detection of pancreatic cancer. Collectively, the 41 new pipeline enhanced our understanding of cfDNA biology and provide new insights for 42 liquid biopsy. 43 44 MAIN TEXT 45 65 sequencing.(Aravanis et al, 2017; Zill et al, 2015) Moreover, the noninvasive nature of cfDNA 66 analysis enables doctors to monitor disease progression.(Couraud et al, 2014; Murtaza et al, 2013; 67 Zill et al, 2015) However, cfDNA analysis using large-scale next-generation sequencing (NGS) 68 has been largely confined to advanced or metastatic cancers, in which the ctDNA ( circulating-69 tumor DNA ) fraction is higher and is more readily detectable.(Gorgannezhad et al, 2018; Haber 70 & Velculescu, 2014) Detection of ctDNA in early-stage cancers is still filled with cautionary tales 71 that highlight the technical challenges in this field. Recently, Velculescu et al reported improved 72 targeted error correction sequencing ( TEC-Seq ) as an efficient approach for the detection of 73 ctDNA in early-stage colorectal, ovarian, breast, and lung cancers, with a detection rate ranging 74 from 59% to 71%.(Phallen et al, 2017) The massive parallel sequencing approach provides an 75 applicable paradigm guiding cfDNA analysis in early-stage cancers. 76 However, the performance of existing approaches is limited in cfDNA analysis in early-77 stage pancreatic cancers. This limitation may be partially because of a lower ctDNA content in 78 the circulation of pancreatic cancers.(Aravanis et al, 2017) Moreover, the biological features of 79

show abstract

“…Patients were followed up every 3 to 5 months by a full-time clinical investigator as previously described. (Liu et al, 2016; Zhou et al, 2017)…”

Section: Methodsmentioning

confidence: 99%

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer

Liu

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Serum expression of carcinoembryonic antigen (CEA, CD66e, CEACAM5) has been known for some time to be a prognostic biomarker in PDAC, albeit with rather poor sensitivity and specificity [ 77 ]. Boonstra et al used a single chain antibody fragment (scFv) that binds to CEA and labelled it with the near-infrared fluorescent dye 800CW [ 78 ], and evaluated it in a mouse model of colorectal cancer (Fig.…”

Section: Cathepsinsmentioning

confidence: 99%

Translational molecular imaging in exocrine pancreatic cancer

Cornelissen

Knight

Mukherjee

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.

show abstract

“… 33 Moreover, plasma levels of miR-16 and miR-196a in combination with CA 19-9 have been shown to work very efficiently for improving the prognostic prediction of early PDAC. 5 Furthermore, another group of researchers observed much higher levels of circulating miR-200a, 200b, and 210 in the plasma of PDAC patients. 34 …”

Section: Role Of Mirnas In the Diagnosis Of Pdacmentioning

confidence: 99%

“… 3 Thus, in light of the disappointing statistics in the prognosis of PDAC, there is an urgent, unmet need for development of valid, reliable biomarkers for early detection and monitoring of PDAC. The current most widely used biomarkers for PDAC are carbohydrate antigen 19-9 (CA19-9), 4 carcinoembryonic antigen, 5 and/or genetic markers such as K-RAS and p53. 6 However, these markers are neither sensitive nor specific for screening, but are used to follow known disease if they were initially elevated, and are not recommended for screening and diagnosis of early disease.…”

Section: Introductionmentioning

confidence: 99%

The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma

Ren¹,

Yu²

2018

TCRM

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expression of multitude number of genes. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for prognosis in PDAC patients. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, chemoresistance, and prognosis in PDAC patients.

show abstract

Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort

Cited by 21 publications

References 26 publications

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer

Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer

Translational molecular imaging in exocrine pancreatic cancer

The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About